Inter-firm R&D partnering in pharmaceutical biotechnology since 1975 : trends, patterns, and networks

A.H.W.M. Roijakkers, J. Hagedoorn

Research output: Contribution to journalArticleAcademicpeer-review

157 Citations (Scopus)

Abstract

This paper analyses a large, longitudinal database on inter-firm R&D partnerships formed in the high-tech pharmaceutical biotechnology industry since 1975. Our research indicates an overall growth in the number of annually, newly established R&D partnerships where research partners consistently prefer contractual partnerships to equity-based alliances. In the networks that develop through these R&D partnerships, small, entrepreneurial biotechnological companies take a leading role during the 1980s when biotechnology first became relevant for the pharmaceutical industry. The 1990s, however, show a different pattern with established, large pharmaceutical companies becoming more dominant, acting as nodal players with multiple partnerships with a variety of other companies.
Original languageEnglish
Pages (from-to)431-446
JournalResearch Policy
Volume35
Issue number3
DOIs
Publication statusPublished - 2006

Fingerprint

Biotechnology
Drug products
Industry
Partnering
Pharmaceuticals

Cite this

Roijakkers, A.H.W.M. ; Hagedoorn, J. / Inter-firm R&D partnering in pharmaceutical biotechnology since 1975 : trends, patterns, and networks. In: Research Policy. 2006 ; Vol. 35, No. 3. pp. 431-446.
@article{22dd6e61809646a2a04c9fa888d5ee15,
title = "Inter-firm R&D partnering in pharmaceutical biotechnology since 1975 : trends, patterns, and networks",
abstract = "This paper analyses a large, longitudinal database on inter-firm R&D partnerships formed in the high-tech pharmaceutical biotechnology industry since 1975. Our research indicates an overall growth in the number of annually, newly established R&D partnerships where research partners consistently prefer contractual partnerships to equity-based alliances. In the networks that develop through these R&D partnerships, small, entrepreneurial biotechnological companies take a leading role during the 1980s when biotechnology first became relevant for the pharmaceutical industry. The 1990s, however, show a different pattern with established, large pharmaceutical companies becoming more dominant, acting as nodal players with multiple partnerships with a variety of other companies.",
author = "A.H.W.M. Roijakkers and J. Hagedoorn",
year = "2006",
doi = "10.1016/j.respol.2006.01.006",
language = "English",
volume = "35",
pages = "431--446",
journal = "Research Policy",
issn = "0048-7333",
publisher = "Elsevier",
number = "3",

}

Inter-firm R&D partnering in pharmaceutical biotechnology since 1975 : trends, patterns, and networks. / Roijakkers, A.H.W.M.; Hagedoorn, J.

In: Research Policy, Vol. 35, No. 3, 2006, p. 431-446.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Inter-firm R&D partnering in pharmaceutical biotechnology since 1975 : trends, patterns, and networks

AU - Roijakkers, A.H.W.M.

AU - Hagedoorn, J.

PY - 2006

Y1 - 2006

N2 - This paper analyses a large, longitudinal database on inter-firm R&D partnerships formed in the high-tech pharmaceutical biotechnology industry since 1975. Our research indicates an overall growth in the number of annually, newly established R&D partnerships where research partners consistently prefer contractual partnerships to equity-based alliances. In the networks that develop through these R&D partnerships, small, entrepreneurial biotechnological companies take a leading role during the 1980s when biotechnology first became relevant for the pharmaceutical industry. The 1990s, however, show a different pattern with established, large pharmaceutical companies becoming more dominant, acting as nodal players with multiple partnerships with a variety of other companies.

AB - This paper analyses a large, longitudinal database on inter-firm R&D partnerships formed in the high-tech pharmaceutical biotechnology industry since 1975. Our research indicates an overall growth in the number of annually, newly established R&D partnerships where research partners consistently prefer contractual partnerships to equity-based alliances. In the networks that develop through these R&D partnerships, small, entrepreneurial biotechnological companies take a leading role during the 1980s when biotechnology first became relevant for the pharmaceutical industry. The 1990s, however, show a different pattern with established, large pharmaceutical companies becoming more dominant, acting as nodal players with multiple partnerships with a variety of other companies.

U2 - 10.1016/j.respol.2006.01.006

DO - 10.1016/j.respol.2006.01.006

M3 - Article

VL - 35

SP - 431

EP - 446

JO - Research Policy

JF - Research Policy

SN - 0048-7333

IS - 3

ER -